Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 9, 2014, Pages 3466-3471

  Ischenko, Irene ^a   Petrenko, Oleksi ^a   Hayman, Michael J ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Cell of origin; Pancreatic ductal adenocarcinoma

Indexed keywords

CD133 ANTIGEN; CD24 ANTIGEN; CELL SURFACE MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROTEIN KRT19; STEM CELL ANTIGEN 1; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

ADULT; ADULT STEM CELL; ANAPLASTIC CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL SURFACE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE MUTATION; METASTASIS POTENTIAL; MOUSE; MOUSE MODEL; NECK METASTASIS; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS CELL; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

CELL OF ORIGIN; PANCREATIC DUCTAL ADENOCARCINOMA;

ANIMALS; BLOTTING, WESTERN; FLOW CYTOMETRY; HOMEODOMAIN PROTEINS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MICE, NUDE; MUTATION, MISSENSE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895785410     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1319911111     Document Type: Article

References (55)

1. Aguirre AJ, et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17(24):3112-3126.
2. Bardeesy N, et al. (2006) Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103(15):5947-5952.
3. Guerra C, et al. (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11(3):291-302.
4. Gidekel Friedlander SY, et al. (2009) Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16(5):379-389.
5. Collins MA, et al. (2012) Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS ONE 7(12):e49707.
6. Reichert M, Rustgi AK (2011) Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 121(12):4572-4578.
7. Jonkers YM, Ramaekers FC, Speel EJ (2007) Molecular alterations during insulinoma tumorigenesis. Biochim Biophys Acta 1775(2):313-332.
8. Guerra C, et al. (2011) Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19(6):728-739.
9. Guerra C, et al. (2003) Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4(2):111-120.
10. Tuveson DA, et al. (2004) Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5(4):375-387.
11. Ischenko I, Zhi J, Moll UM, Nemajerova A, Petrenko O (2013) Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci USA 110(10):3937-3942.
12. Zhang Z, et al. (2001) Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29(1):25-33.
13. Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA (2005) Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-rasdirected therapy. Mol Cancer Res 3(7):413-423.
14. Qiu W, et al. (2011) Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2(11):862-873.
15. Sarkisian CJ, et al. (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9(5):493-505.
16. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80(2):179-185.
17. Parikh N, Shuck RL, Nguyen TA, Herron A, Donehower LA (2012) Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses. Mol Cancer Res 10(6):845-855.
18. Bazarov AV, et al. (2001) A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res 61(3):1178-1186.
19. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U (2002) c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: Incidence, mechanisms, and clinical significance. Mod Pathol 15(4):462-469.
20. Mahlamäki EH, et al. (2002) Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 35(4):353-358.
21. Sears R, Leone G, DeGregori J, Nevins JR (1999) Ras enhances Myc protein stability. Mol Cell 3(2):169-179.
22. Ardito CM, et al. (2012) EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22(3):304-317.
23. Navas C, et al. (2012) EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22(3):318-330.
24. Jones S, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801-1806.
25. Bardeesy N, et al. (2006) Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20(22): 3130-3146.
26. Ijichi H, et al. (2006) Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20(22):3147-3160.
27. Kim CF, et al. (2005) Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121(6):823-835.
28. Haigis KM, et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40(5): 600-608.
29. Rovira M, et al. (2010) Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci USA 107(1):75-80.
30. Li C, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3): 1030-1037.
31. Hermann PC, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3): 313-323.
32. Seaberg RM, et al. (2004) Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat Biotechnol 22(9): 1115-1124.
33. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A (2008) Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer 8:48.
34. Lardon J, Corbeil D, Huttner WB, Ling Z, Bouwens L (2008) Stem cell marker prominin-1/AC133 is expressed in duct cells of the adult human pancreas. Pancreas 36(1):e1-e6.
35. Delmore JE, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904-917.
36. Brembeck FH, et al. (2003) The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res 63(9):2005-2009.
37. Ray KC, et al. (2011) Epithelial tissues have varying degrees of susceptibility to Kras (G12D)-initiated tumorigenesis in a mouse model. PLoS ONE 6(2):e16786.
38. Hingorani SR, et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5):469-483.
39. Habbe N, et al. (2008) Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci USA 105(48):18913-18918.
40. Stanger BZ, et al. (2005) Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8(3):185-195.
41. Kopp JL, et al. (2012) Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22(6):737-750.
42. De La O JP, et al. (2008) Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA 105(48):18907-18912.
43. Huch M, et al. (2013) Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J 32(20):2708-2721.
44. Jin L, et al. (2013) Colony-forming cells in the adult mouse pancreas are expandable in Matrigel and form endocrine/acinar colonies in laminin hydrogel. Proc Natl Acad Sci USA 110(10):3907-3912.
45. Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418(6900):823.
46. Hynes RO (2003) Metastatic potential: Generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113(7):821-823.
47. Yachida S, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114-1117.
48. Campbell PJ, et al. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109-1113.
49. Rhim AD, et al. (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2):349-361.
50. Haeno H, et al. (2012) Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 148(1-2):362-375.
51. Nguyen DX, Bos PD, Massagué J (2009) Metastasis: From dissemination to organspecific colonization. Nat Rev Cancer 9(4):274-284.
52. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20(10):1218-1249.
53. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3:157-188.
54. Yachida S, et al. (2012) Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res 18(22):6339-6347.
55. Jacks T, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4(1):1-7.